About Egalet (NASDAQ:EGLT)
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$16.96 million
Price / Sales2.06
Price / CashN/A
Book Value$0.21 per share
Price / Book3.62
Return on EquityN/A
Return on Assets-73.83%
Egalet (NASDAQ:EGLT) Frequently Asked Questions
What is Egalet's stock symbol?
Egalet trades on the NASDAQ under the ticker symbol "EGLT."
How were Egalet's earnings last quarter?
Egalet Corp (NASDAQ:EGLT) released its quarterly earnings data on Thursday, August, 4th. The specialty pharmaceutical company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.15. The specialty pharmaceutical company had revenue of $3.45 million for the quarter, compared to the consensus estimate of $3.83 million. The company's revenue for the quarter was up 259.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.03) EPS. View Egalet's Earnings History.
When will Egalet make its next earnings announcement?
Where is Egalet's stock going? Where will Egalet's stock price be in 2018?
5 brokerages have issued 1-year price objectives for Egalet's stock. Their predictions range from $1.50 to $9.50. On average, they anticipate Egalet's share price to reach $6.20 in the next year. View Analyst Ratings for Egalet.
Who are some of Egalet's key competitors?
Some companies that are related to Egalet include Aptevo Therapeutics (APVO), Applied Genetic Technologies (AGTC), Galmed Pharmaceuticals (GLMD), Axsome Therapeutics (AXSM), Xenon Pharmaceuticals (XENE), Versartis (VSAR), Arcturus Therapeutics (ARCT), Rexahn Pharmaceuticals (RNN), PLx Pharma (PLXP), Synthetic Biologics (SYN), pSivida (PSDV), OptiBiotix Health (OPTI), Actinium Pharmaceuticals (ATNM), Capricor Therapeutics (CAPR), Avacta Group (AVCT), Pain Therapeutics (PTIE), ANGLE (AGL) and Celsion (CLSN).
Who are Egalet's key executives?
Egalet's management team includes the folowing people:
- Timothy P. Walbert, Independent Chairman of the Board (Age 50)
- Robert Radie, President, Chief Executive Officer, Director (Age 52)
- Stanley J. Musial, Chief Financial Officer, Executive Vice President, Secretary (Age 55)
- Mark Strobeck Ph.D., Chief Operating Officer, Executive Vice President (Age 45)
- Paul C. Varki J.D., Senior Vice President, General Counsel
- E. Blair Clark-Schoeb, Senior Vice President - Communications
- Karsten Lindhardt Ph.D., Senior Vice President - Research & Development (Age 44)
- Barbara Carlin, Chief Accounting Officer (Age 41)
- Jeffrey M. Dayno M.D., Chief Medical Officer (Age 59)
- Patrick M. Shea, Chief Commercial Officer
Who owns Egalet stock?
Egalet's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.57%). Company insiders that own Egalet stock include Deanne F Melloy, Jeffrey M Dayno, Mark Strobeck, Patrick M Shea, Paul Varki, Robert S Radie and Stan Musial. View Institutional Ownership Trends for Egalet.
Who bought Egalet stock? Who is buying Egalet stock?
How do I buy Egalet stock?
Shares of Egalet can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Egalet's stock price today?
One share of Egalet stock can currently be purchased for approximately $0.76.
How big of a company is Egalet?
Egalet has a market capitalization of $36.99 million and generates $16.96 million in revenue each year. The specialty pharmaceutical company earns $-90,630,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis. Egalet employs 154 workers across the globe.
How can I contact Egalet?
Egalet's mailing address is 600 LEE ROAD SUITE 100, WAYNE PA, 19087. The specialty pharmaceutical company can be reached via phone at 610-833-4200 or via email at [email protected]
MarketBeat Community Rating for Egalet (EGLT)MarketBeat's community ratings are surveys of what our community members think about Egalet and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Egalet (NASDAQ:EGLT) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.60||2.60||2.80||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$6.20||$6.20||$7.10||$7.10|
|Price Target Upside: ||501.94% upside||501.94% upside||755.42% upside||517.39% upside|
Egalet (NASDAQ:EGLT) Consensus Price Target History
Egalet (NASDAQ:EGLT) Analyst Ratings History
(Data available from 2/22/2016 forward)
Egalet (NASDAQ:EGLT) Earnings History and Estimates Chart
Egalet (NASDAQ EGLT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/8/2018|| || || || || || || || |
|11/8/2017||Q3 2017||($0.47)||($0.46)||$7.46 million||$6.65 million||View||N/A|
|8/9/2017||Q2 2017||($0.94)||($1.04)||$6.68 million||$6.26 million||View||Listen|
|5/10/2017||Q1 2017||($0.90)||($1.02)||$6.92 million||$5.57 million||View||N/A|
|3/9/2017||Q4 2016||($0.92)||($0.87)||$5.37 million||$6.14 million||View||Listen|
|11/4/2016||Q316||($0.90)||($1.10)||$4.50 million||$4.70 million||View||N/A|
|8/4/2016||Q216||($0.82)||($0.97)||$3.83 million||$3.45 million||View||N/A|
|5/10/2016||Q116||($0.87)||($0.76)||$3.50 million||$2.70 million||View||Listen|
|3/8/2016||Q415||($0.91)||($0.28)||$2.80 million||$2.10 million||View||N/A|
|11/4/2015||Q315||($0.90)||($0.81)||$1.62 million||$1.30 million||View||N/A|
|8/6/2015||Q215||($1.02)||($0.98)||$0.95 million||$0.96 million||View||N/A|
|5/7/2015||Q1 2015||($0.98)||($1.02)||$3.00 million||$0.81 million||View||N/A|
|3/16/2015||Q414||($0.71)||($0.52)||$0.30 million||$0.83 million||View||N/A|
Egalet (NASDAQ:EGLT) Earnings Estimates
Current Year EPS Consensus Estimate: $-2.81 EPS
Next Year EPS Consensus Estimate: $-1.26 EPS
Dividend History for Egalet (NASDAQ:EGLT)
No dividend announcements for this company have been tracked by MarketBeat.com
Egalet (NASDAQ EGLT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 47.85%
Egalet (NASDAQ EGLT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/2/2018||Patrick M Shea||Insider||Sell||910||$1.00||$910.00||37,020|| |
|10/2/2017||Mark Strobeck||COO||Sell||8,700||$1.29||$11,223.00||12,080|| |
|10/2/2017||Patrick M Shea||Insider||Sell||910||$1.30||$1,183.00||37,930|| |
|7/3/2017||Patrick M. Shea||Insider||Sell||910||$2.35||$2,138.50|| |
|7/3/2017||Paul Varki||SVP||Sell||806||$2.35||$1,894.10|| |
|7/3/2017||Stan Musial||CFO||Sell||3,480||$2.36||$8,212.80||42,407|| |
|6/30/2017||Mark Strobeck||COO||Sell||8,700||$2.39||$20,793.00||20,780|| |
|4/3/2017||Paul Varki||SVP||Sell||806||$5.05||$4,070.30||28,820|| |
|4/3/2017||Stan Musial||CFO||Sell||8,613||$5.04||$43,409.52||45,887|| |
|3/31/2017||Jeffrey M Dayno||Insider||Sell||536||$5.16||$2,765.76||18,212|| |
|3/31/2017||Mark Strobeck||COO||Sell||8,700||$5.11||$44,457.00||29,480|| |
|3/20/2017||Patrick M Shea||Insider||Sell||4,250||$4.75||$20,187.50||38,250|| |
|1/3/2017||Jeffrey M Dayno||Insider||Sell||536||$7.75||$4,154.00||18,748|| |
|1/3/2017||Paul Varki||SVP||Sell||806||$7.75||$6,246.50||29,626|| |
|1/3/2017||Stan Musial||CFO||Sell||13,480||$7.73||$104,200.40||54,500|| |
|12/30/2016||Mark Strobeck||COO||Sell||8,700||$7.81||$67,947.00||38,180|| |
|10/3/2016||Paul Varki||SVP||Sell||806||$7.56||$6,093.36||30,432|| |
|10/3/2016||Robert S Radie||Insider||Sell||15,000||$7.47||$112,050.00||234,900|| |
|10/3/2016||Stan Musial||CFO||Sell||13,480||$7.47||$100,695.60||67,980|| |
|9/30/2016||Jeffrey M Dayno||Insider||Sell||536||$7.69||$4,121.84||19,284|| |
|9/30/2016||Mark Strobeck||COO||Sell||33,700||$7.58||$255,446.00||71,880|| |
|7/6/2016||Robert S Radie||CEO||Sell||15,000||$5.01||$75,150.00||259,900|| |
|7/5/2016||Robert S Radie||CEO||Sell||5,000||$4.94||$24,700.00||259,900|| |
|7/5/2016||Stan Musial||CFO||Sell||13,480||$5.06||$68,208.80||84,940|| |
|7/1/2016||Robert S Radie||CEO||Sell||5,000||$5.07||$25,350.00||259,900|| |
|7/1/2016||Stan Musial||CFO||Sell||10,000||$5.06||$50,600.00||84,940|| |
|6/30/2016||Jeffrey M Dayno||Insider||Sell||536||$4.65||$2,492.40||19,820|| |
|4/5/2016||Deanne F Melloy||Insider||Sell||860||$6.96||$5,985.60||33,420|| |
|4/5/2016||Robert S Radie||CEO||Sell||5,000||$6.99||$34,950.00||264,900|| |
|4/4/2016||Robert S Radie||CEO||Sell||10,000||$6.97||$69,700.00||274,900|| |
|1/11/2016||Robert S. Radie||CEO||Sell||10,000||$9.65||$96,500.00||279,900|| |
|1/6/2016||Robert S. Radie||CEO||Sell||5,000||$10.52||$52,600.00||298,900|| |
|10/6/2015||Deanne F Melloy||Insider||Sell||860||$11.42||$9,821.20||35,140|| |
|10/1/2015||Robert S Radie||CEO||Sell||15,000||$12.27||$184,050.00||303,900|| |
|10/1/2015||Stan Musial||CFO||Sell||8,480||$12.32||$104,473.60||101,900|| |
|9/30/2015||Mark Strobeck||Insider||Sell||5,220||$12.56||$65,563.20||106,680|| |
|7/8/2015||Robert S Radie||CEO||Sell||6,000||$11.97||$71,820.00|| |
|7/6/2015||Robert S Radie||CEO||Sell||9,000||$12.53||$112,770.00|| |
|7/1/2015||Mark Strobeck||Insider||Sell||10,440||$12.98||$135,511.20|| |
|7/1/2015||Stan Musial||CFO||Sell||8,480||$13.20||$111,936.00|| |
|4/1/2015||Robert S Radie||CEO||Sell||11,130||$11.25||$125,212.50|| |
|2/3/2015||Jeffrey M Dayno||Insider||Sell||2,500||$8.87||$22,175.00|| |
|1/2/2015||Mark Strobeck||Insider||Sell||3,480||$5.09||$17,713.20|| |
|1/2/2015||Robert S Radie||CEO||Sell||11,130||$5.11||$56,874.30|| |
|9/10/2014||Robert S Radie||CEO||Sell||40,040||$9.61||$384,784.40|| |
|9/8/2014||Robert S Radie||CEO||Sell||49,000||$9.74||$477,260.00|| |
|8/13/2014||Mark Strobeck||Insider||Sell||5,135||$9.20||$47,242.00|| |
|8/11/2014||Mark Strobeck||Insider||Sell||5,700||$10.28||$58,596.00|| |
|8/7/2014||Mark Strobeck||Insider||Sell||3,085||$11.50||$35,477.50|| |
|8/7/2014||Stan Musial||CFO||Sell||13,920||$11.05||$153,816.00|| |
|2/11/2014||Jean Francois Formela||Director||Buy||41,667||$12.00||$500,004.00|| |
|2/11/2014||Life Science Ventures Sunstone||Major Shareholder||Buy||133,333||$12.00||$1,599,996.00|| |
Egalet (NASDAQ EGLT) News Headlines
Egalet (NASDAQ:EGLT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Egalet (NASDAQ:EGLT) Income Statement, Balance Sheet and Cash Flow Statement
Egalet (NASDAQ EGLT) Stock Chart for Thursday, February, 22, 2018